f5 Therapeutics’ is a privately owned, Targeted Protein Degradation (TPD) company based in San Diego California. Our NExMods™ (Neosubstrate Expression Modulators) platform is expanding the scope of degradable targets to fight disease. Our methods allow access to the abundance of undiscovered neosubstrates available for degradation with potential in multiple indications. We identify these new targets in context with cellular assays allowing us to fully realize the wide class of neosubstrates afforded by cereblon. We have discovered 11 novel oncology targets for degradation that are not being reported by other molecular glue companies. NExMods™ have demonstrated in vitro POC across five therapeutic areas (immuno-oncology, Wnt-driven cancers, auto-immune disease, NASH, liver fibrosis) and demonstrated 100X cereblon binding potency versus known clinical IMiDs. In addition to our monotherapy assets, we are committed to exploring our library conjugated with targeted antibodies in oncology. While there is great momentum in the ADC world, there are still shortcomings in traditional ADC development. A growing interest in utilizing targeted protein degraders instead of cytotoxic agents as the ADC payload has garnered very recent headlines. These ‘Degrader Antibody Conjugates’ are growing in interest to big pharma and f5 Therapeutics wants to be at the forefront of this wave of innovation. We have discovered a number of novel ‘payloads’ we are looking to get into PoC testing through funding/partnering.